Abstract: Objective To explore the prognosis of drug therapy and PCI treatment of non-ST segment elevation myocardial infarction. Methods Total 623 cases of non-ST-segment-elevation myocardial infarction receiving drug treatment(drug treatment group) and 412 cases of drug therapy with PCI(drug therapy+PCI treatment group) in Taizhou First People's Hospital were enrolled into this study.The incidence of endpoint events and median survival time in both groups were observed,and TIMI score and age differentiation of endpoint events were compared. Results The incidence of the primary endpoint events and secondary endpoint events of the drug treatment group were higher than that of the drug therapy+PCI treatment group(P<0.05).The median survival time of the primary endpoint events and secondary endpoint events of drug treatment group were lower than that of drug therapy +PCI treatment group(P<0.05).The difference of the incidence of primary endpoint events and secondary endpoint events in the drug treatment group and drug therapy+PCI treatment group with TIMI score 0-2 was not statistically significant(P>0.05),the incidence of primary endpoint events and secondary endpoint events in the drug treatment group with TIMI score 3-5 and 6-7 were higher than that of the drug therapy+PCI treatment group(P<0.05).The difference of incidence of the primary endpoint events and secondary endpoint events in the drug treatment group and drug therapy+PCI treatment group with <65-year-old patient was not statistically significant(P>0.05),the incidence of primary endpoint events and secondary endpoint events in the drug treatment group with 65-75 years and >75 years were higher than that of the drug therapy+PCI group(P<0.05). Conclusion PCI therapy can reduce the incidence of adverse outcome events of non-ST-segment-elevation myocardial infarction,prolonged median survival time,improve the prognosis of patients with TIMI grade intermediate-risk or high-risk and older more than 65 years.